Abstract
Patients with chronic hepatitis B are at risk of reactivation of viral hepatitis during chemotherapy. We report a case of hepatitis B reactivation occurring in association with single-agent gemcitabine chemotherapy in the absence of significant myelosuppression. Gemcitabine is a nucleoside analog that can affect cell-mediated immunity, and this may contribute to an increased risk of reactivation of hepatitis B. We advise caution when administering chemotherapy to patients who are hepatitis B surface antigen positive, even when using relatively nontoxic palliative single-agent cytotoxic drugs. Monitoring of liver function tests will identify hepatitis, and measurement of hepatitis B DNA levels may help distinguish chemotherapy-induced hepatitis from hepatitis B virus reactivation.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Lok ASF, et al. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Gastroenterology 1991;100(1):182–188.
Liang R, Lau GKK, Kwong YL. Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carrier: a review of the problem. J. Clin. Oncol. 1999;17(1):394–398.
Perrillo RP. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 2001;120(3):1009–1022.
Yeo W, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. Proc Am Soc Clin Oncol 2000;19:600a (abstr 2361).
Yeo W, et al. Lamivudine prevents hepatitis B virus (HBV) reactivation in HBV carriers undergoing cytotoxic chemotherapy (CT)—a prospective study. Proc. Am Soc Clin Oncol 2002;21:362a (abstr 1447).
Alvino E, Fuggetta MP, Tricarico M, Bonmassar E. 2′-2′-Difluorodeoxycytidine: in vitro effects on cell-mediated immune response. Anticancer Res 1998;18(5A):3597–3602.
Mok TSK, et al. A phase II study of gemcitabine plus oral etoposide in the treatment of patients with advanced non-small cell lung carcinoma. Cancer 2000;89(3):543–550.
Fischer DS, Knobf MT, Durivage HJ. Chemotherapy drugs, In: Fischer DS (ed). The Cancer Chemotherapy Handbook, 5th ed. Mosby: St Louis, 1997, p. 128.
Noble S, Goa KL. Gemcitabine: a review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer. Drugs 1997;54(3):447–472.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cheong, K., Li, J. & Karapetis, C.S. Gemcitabine and reactivation of hepatitis B. Med Oncol 20, 385–387 (2003). https://doi.org/10.1385/MO:20:4:385
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1385/MO:20:4:385